FIGURE

Figure 1

ID

ZDB-FIG-251225-78

Publication

Colin et al., 2025 - MMS22L is a novel key actor of normal and pathological erythropoiesis

Other Figures

All Figure Page

Back to All Figure Page

Figure 1

CombinedMMS22LandCDAN1haplo‐insufficiency alters in vivo erythropoiesis. (A) Electropherograms of the patient, her brother, and son showing Sanger sequence validation of the MMS22L Q732X and CDAN1 R725W mutations. Arrows indicate the position of the nucleotide's substitutions. (B) Quantification of the o‐dianisidine positive area in the yolk sac of each embryo injected with the indicated morpholinos. Analysis was performed using the ImageJ software. Data are representative of two independent experiments. (C) Representative images of 48 hpf o–dianisidine–stained embryos injected with the indicated morpholinos. MOs used in this experience result in a 50% downregulation of gene expression. P‐values are determined by a two‐tailed t‐test. ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	WT + MO1-mms22l WT + MO3-cdan1 WT + MO1-mms22l + MO3-cdan1
Knockdown Reagents:	MO1-mms22l MO3-cdan1
Observed In:	ball hemoglobin whole organism
Stage:	Long-pec

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Hemasphere